{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that alpha-synuclein is implicated in both neuronal plasticity and neurodegenerative disease.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links alpha-synuclein to neurodegenerative disease, establishing a relevant disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses enzyme inhibition assays to investigate the functional effect of alpha-synuclein variants on PLD2 activity.",
          "judgment": "Yes",
          "reasoning": "Enzyme inhibition assays are a valid approach to assess the functional impact of variants affecting protein activity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper states that PLD2 inhibition was measured, but doesn't detail precise experimental replicates or descriptions of positive and negative controls specifically for A30P.",
          "judgment": "No",
          "reasoning": "The paper does not explicitly state the use of basic controls (wild-type, null) or number of replicates."
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "PLD2 inhibition assays are a standard technique in the field.",
          "judgment": "Yes",
          "reasoning": "PLD2 inhibition assays are broadly accepted and validated in the field.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P variant is associated with increased PLD2 inhibition. While basic controls are not detailed, the assay is well-established, supporting a pathogenic interpretation."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that alpha-synuclein is implicated in both neuronal plasticity and neurodegenerative disease.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links alpha-synuclein to neurodegenerative disease, establishing a relevant disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses enzyme inhibition assays to investigate the functional effect of alpha-synuclein variants on PLD2 activity.",
          "judgment": "Yes",
          "reasoning": "Enzyme inhibition assays are a valid approach to assess the functional impact of variants affecting protein activity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper states that PLD2 inhibition was measured, but doesn't detail precise experimental replicates or descriptions of positive and negative controls specifically for A53T.",
          "judgment": "No",
          "reasoning": "The paper does not explicitly state the use of basic controls (wild-type, null) or number of replicates."
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "PLD2 inhibition assays are a standard technique in the field.",
          "judgment": "Yes",
          "reasoning": "PLD2 inhibition assays are broadly accepted and validated in the field.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A53T variant exhibits increased PLD2 inhibition. While basic controls are not detailed, the assay is well-established, supporting a pathogenic interpretation."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "D",
          "alt": "N",
          "position": "83"
        },
        "variant_string_id": "SNCA D83N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that alpha-synuclein is implicated in both neuronal plasticity and neurodegenerative disease.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links alpha-synuclein to neurodegenerative disease, establishing a relevant disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses enzyme inhibition assays to investigate the functional effect of alpha-synuclein variants on PLD2 activity.",
          "judgment": "Yes",
          "reasoning": "Enzyme inhibition assays are a valid approach to assess the functional impact of variants affecting protein activity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper states that PLD2 inhibition was measured, but doesn't detail precise experimental replicates or descriptions of positive and negative controls specifically for D83N.",
          "judgment": "No",
          "reasoning": "The paper does not explicitly state the use of basic controls (wild-type, null) or number of replicates."
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "PLD2 inhibition assays are a standard technique in the field.",
          "judgment": "Yes",
          "reasoning": "PLD2 inhibition assays are broadly accepted and validated in the field.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The D83N variant exhibits increased PLD2 inhibition. While basic controls are not detailed, the assay is well-established, supporting a pathogenic interpretation."
    }
  ]
}